Author information

¹Oregon Health & Science University, Division of General Internal Medicine & Geriatrics, Portland, OR, United States of America. Electronic address: spencerh@ohsu.edu.

²Comagine Health, Portland, OR, United States of America.

³Oregon Health & Science University, Division of General Internal Medicine & Geriatrics, Portland, OR, United States of America.

⁴Oregon State University, College of Pharmacy, Corvallis, OR, United States of America.

⁵Oregon Health Authority, Behavioral Health Services, Health Systems Division, United States of America.

⁶Oregon Health & Science University, Division of General Internal Medicine & Geriatrics, Portland, OR, United States of America; Central City Concern, Portland, OR, United States of America.

Abstract

Introduction: The opioid crisis and the hepatitis C virus epidemic perpetuate and potentiate each other in a syndemic with escalating morbidity. Policy-driven funding can help resolve the syndemic through collaborative solutions that rapidly translate evidence-based interventions into real-world applications.

Methods: We report development and programmatic evaluation of Peer-Assisted Telemedicine for Hepatitis C (PATHS), which utilizes State Opioid Response (SOR) funding to scale-up a positive randomized trial of peer-assisted telemedicine HCV treatment. PATHS employs staff within an academic medical center and partners with people with lived experience of drug use, "peers," to recruit rural-dwelling people who use drugs living with HCV. PATHS staff record patient data by abstracting clinical records or directly communicating with patients and peers. Peers are funded by a separate SOR-supported program administered through the state health authority. Peers support patients through HCV screening, treatment initiation via telemedicine, adherence, and cure.

Results: Between March 2021 and June 2024, PATHS expanded to 18 of Oregon's 36 counties. In that time, PATHS diagnosed 198 rural PWUD with HCV. One hundred sixty-seven (84.3 %) linked to telemedicine and of these, 145 (86.8 %) initiated treatment. Of those who initiated treatment, 91 (62.8 %) completed treatment, of which 61 (67.0 %) are cured.

Conclusions: By rapidly translating a clinical innovation in HCV treatment to achieve highly effective real-world results, PATHS models how policy-driven funding can facilitate collaboration between community partners, academic medical centers, and state health departments to end the opioid-HCV syndemic.